Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica K Gordon

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
The Journal of Rheumatology|March 17, 2017
Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate TreatmentD James Haddon, Hannah E Wand, Justin A Jarrell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 1, 2025
Skin biopsies enhance prediction of clinical trajectory in diffuse cutaneous systemic sclerosisKimberly S Lakin, John Spivack, Jessica K Gordon, et al.
Science Translational Medicine|January 12, 2018
Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8Marie Dominique Ah Kioon, Claudio Tripodo, David Fernandez, et al.
Arthritis Research & Therapy|September 5, 2019
A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcersVivek Nagaraja, Cathie Spino, Erica Bush, et al.
Clinical and Experimental Rheumatology|October 3, 2018
Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trialJulio C Mantero, Nina Kishore, Jessica Ziemek, et al.
Arthritis Research & Therapy|August 19, 2015
Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trialJessica K Gordon, Viktor Martyanov, Cynthia Magro, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 27, 2017
Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot TrialJessica K Gordon, Viktor Martyanov, Jennifer M Franks, et al.
Annals of the Rheumatic Diseases|March 15, 2011
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trialRobert F Spiera, Jessica K Gordon, Jamie N Mersten, et al.
Seminars in Arthritis and Rheumatism|June 8, 2024
COVID-19 vaccinations and infections among individuals with systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort studyKimberly S Lakin, Yin Wu, Jessica K Gordon, et al.
Clinical and Experimental Rheumatology|August 6, 2013
Treatment of early diffuse systemic sclerosis skin diseaseTracy M Frech, Victoria K Shanmugam, Ami A Shah, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
The Journal of Rheumatology|March 17, 2017
Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate TreatmentD James Haddon, Hannah E Wand, Justin A Jarrell, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 1, 2025
Skin biopsies enhance prediction of clinical trajectory in diffuse cutaneous systemic sclerosisKimberly S Lakin, John Spivack, Jessica K Gordon, et al.
Science Translational Medicine|January 12, 2018
Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8Marie Dominique Ah Kioon, Claudio Tripodo, David Fernandez, et al.
Arthritis Research & Therapy|September 5, 2019
A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcersVivek Nagaraja, Cathie Spino, Erica Bush, et al.
Clinical and Experimental Rheumatology|October 3, 2018
Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trialJulio C Mantero, Nina Kishore, Jessica Ziemek, et al.
Arthritis Research & Therapy|August 19, 2015
Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trialJessica K Gordon, Viktor Martyanov, Cynthia Magro, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 27, 2017
Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot TrialJessica K Gordon, Viktor Martyanov, Jennifer M Franks, et al.
Annals of the Rheumatic Diseases|March 15, 2011
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trialRobert F Spiera, Jessica K Gordon, Jamie N Mersten, et al.
Seminars in Arthritis and Rheumatism|June 8, 2024
COVID-19 vaccinations and infections among individuals with systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort studyKimberly S Lakin, Yin Wu, Jessica K Gordon, et al.
Clinical and Experimental Rheumatology|August 6, 2013
Treatment of early diffuse systemic sclerosis skin diseaseTracy M Frech, Victoria K Shanmugam, Ami A Shah, et al.
Pageof 7